GeoVax Labs, Inc. GOVX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-95.37
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $2.5M | -$21.5M | — | -$21.5M | $3.8M |
| 2024 | $4.0M | -$25.0M | — | -$24.7M | $5.0M |
| 2023 | $0 | -$26.0M | — | -$25.2M | $5.8M |
| 2022 | $81,526 | -$14.0M | — | -$19.2M | $26.6M |
| 2021 | $385,501 | -$18.6M | — | -$11.2M | $4.4M |
| 2020 | $1.8M | -$3.0M | — | -$2.9M | $9.6M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -95.37 (distress)
- Working capital / assets 0.533
- Retained earnings / assets -23.782
- EBIT / assets -3.412
- Equity / liabilities 1.52
Source: SEC EDGAR filings · CIK 0000832489 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.